Tokyo Tape
Sign in
← Toho Holdings

Half-year report · Q2

8129.TEDINET S100URS6
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥755.0bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥1.48T2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥734.8bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥7.4bn2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥6.5bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥8.6bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥21.8bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥7.9bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥8.5bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥13.0bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥5.4bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥20.7bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥8.8bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥5.4bn2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥8.8bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥770.7bnat 2024-09-30Cons.Assets
Total assets¥773.4bnat 2024-03-31Cons.Assets
Total assets¥801.4bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥508.1bnat 2024-09-30Cons.Liabilities
Total liabilities¥524.0bnat 2024-03-31Cons.Liabilities
Net assets / equity¥262.6bnat 2024-09-30Cons.Net assets
Net assets / equity¥249.4bnat 2024-03-31Cons.Net assets
Net assets / equity¥245.1bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥108.2bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥133.0bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥103.9bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥128.7bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥133.5bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥81.8bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow−¥10.7bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥59.9bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥53.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥4.6bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow¥9.1bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow¥3.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥10.2bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥22.2bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥5.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥85.712024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥320.142023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥134.192023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥75.642024-04-01 → 2024-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥286.792023-04-01 → 2024-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥121.192023-04-01 → 2023-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio34.1%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio32.2%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio30.6%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥29.7bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥29.7bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥1.3bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue2024-04-01 → 2024-09-30¥47.1bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2024-04-01 → 2024-09-30¥47.1bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥19m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2024-04-01 → 2024-09-30−¥18m
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2024-04-01 → 2024-09-30¥5.6bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2024-04-01 → 2024-09-30¥1.4bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥4.2bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2024-04-01 → 2024-09-30¥442m
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue2024-04-01 → 2024-09-30¥728.7bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue external2024-04-01 → 2024-09-30¥704.3bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥24.4bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentsegment profit2024-04-01 → 2024-09-30¥8.0bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥3.2bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥2.2bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥994m
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥203m
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥784.6bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥755.0bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2024-09-30¥29.7bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥8.6bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥29.3bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥29.3bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.8bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue2023-04-01 → 2023-09-30¥46.6bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2023-04-01 → 2023-09-30¥46.6bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥7m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2023-04-01 → 2023-09-30¥895m
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2023-04-01 → 2023-09-30¥5.2bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2023-04-01 → 2023-09-30¥1.2bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥4.0bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2023-04-01 → 2023-09-30¥436m
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue2023-04-01 → 2023-09-30¥709.4bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue external2023-04-01 → 2023-09-30¥684.8bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥24.6bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentsegment profit2023-04-01 → 2023-09-30¥6.8bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥3.0bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥2.3bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥678m
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥139m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥764.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥734.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥29.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥8.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 574
ItemContextValueUnit
Other eiPrior1YTDDuration5134000000JPY
Other eiCurrentYTDDuration0JPY
Extraordinary incomePrior1YTDDuration5152000000JPY
Extraordinary incomeCurrentYTDDuration26000000JPY
Loss on disposal of noncurrent assets elPrior1YTDDuration48000000JPY
Loss on disposal of noncurrent assets elCurrentYTDDuration54000000JPY
Impairment loss elPrior1YTDDuration－JPY
Impairment loss elCurrentYTDDuration18000000JPY
Other elPrior1YTDDuration20000000JPY
Other elCurrentYTDDuration8000000JPY
Extraordinary lossPrior1YTDDuration68000000JPY
Extraordinary lossCurrentYTDDuration81000000JPY
Income before income taxesPrior1YTDDuration13029000000JPY
Income before income taxesCurrentYTDDuration8541000000JPY
Income taxes currentPrior1YTDDuration5280000000JPY
Income taxes currentCurrentYTDDuration3629000000JPY
Income taxes deferredPrior1YTDDuration-1039000000JPY
Income taxes deferredCurrentYTDDuration-477000000JPY
Income taxesPrior1YTDDuration4241000000JPY
Income taxesCurrentYTDDuration3151000000JPY
Profit lossPrior1YTDDuration8788000000JPY
Profit lossCurrentYTDDuration5390000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration6000000JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration6000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration8782000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration5383000000JPY
Profit lossPrior1YTDDuration8788000000JPY
Profit lossCurrentYTDDuration5390000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration439000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration2655000000JPY
Share of other comprehensive income of associates accounted for using equity method ociPrior1YTDDuration17000000JPY
Share of other comprehensive income of associates accounted for using equity method ociCurrentYTDDuration-11000000JPY
Other comprehensive incomePrior1YTDDuration457000000JPY
Other comprehensive incomeCurrentYTDDuration2644000000JPY
Comprehensive incomePrior1YTDDuration9246000000JPY
Comprehensive incomeCurrentYTDDuration8035000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration9240000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration8028000000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration6000000JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration6000000JPY
Income before income taxesPrior1YTDDuration13029000000JPY
Income before income taxesCurrentYTDDuration8541000000JPY
Depreciation and amortization ope cfPrior1YTDDuration3098000000JPY
Depreciation and amortization ope cfCurrentYTDDuration2817000000JPY
Impairment loss ope cfPrior1YTDDuration－JPY
Impairment loss ope cfCurrentYTDDuration18000000JPY
Amortization of goodwill ope cfPrior1YTDDuration134000000JPY
Amortization of goodwill ope cfCurrentYTDDuration93000000JPY
Increase decrease in net defined benefit liability ope cfPrior1YTDDuration12000000JPY
Increase decrease in net defined benefit liability ope cfCurrentYTDDuration36000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass